JP2024513514A5 - - Google Patents
Info
- Publication number
- JP2024513514A5 JP2024513514A5 JP2023562500A JP2023562500A JP2024513514A5 JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5 JP 2023562500 A JP2023562500 A JP 2023562500A JP 2023562500 A JP2023562500 A JP 2023562500A JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- natural killer
- combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172424P | 2021-04-08 | 2021-04-08 | |
| US63/172,424 | 2021-04-08 | ||
| US202163290351P | 2021-12-16 | 2021-12-16 | |
| US63/290,351 | 2021-12-16 | ||
| PCT/US2022/023676 WO2022216826A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a cd38-targeted antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513514A JP2024513514A (ja) | 2024-03-25 |
| JP2024513514A5 true JP2024513514A5 (enExample) | 2025-04-14 |
Family
ID=83546555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562500A Withdrawn JP2024513514A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｃｄ３８－標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240115704A1 (enExample) |
| EP (1) | EP4319770A4 (enExample) |
| JP (1) | JP2024513514A (enExample) |
| KR (1) | KR20240024047A (enExample) |
| AU (1) | AU2022253256A1 (enExample) |
| WO (1) | WO2022216826A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316257A (en) * | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
| AU2019271146A1 (en) * | 2018-05-14 | 2020-12-10 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| WO2020101361A1 (ko) * | 2018-11-14 | 2020-05-22 | 주식회사 녹십자랩셀 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
| EP3969004A1 (en) * | 2019-05-14 | 2022-03-23 | Sanofi | Methods of administering anti-cd38 antibody to treat multiple myeloma |
-
2022
- 2022-04-06 AU AU2022253256A patent/AU2022253256A1/en not_active Abandoned
- 2022-04-06 WO PCT/US2022/023676 patent/WO2022216826A1/en not_active Ceased
- 2022-04-06 KR KR1020237038592A patent/KR20240024047A/ko not_active Withdrawn
- 2022-04-06 JP JP2023562500A patent/JP2024513514A/ja not_active Withdrawn
- 2022-04-06 US US18/285,646 patent/US20240115704A1/en active Pending
- 2022-04-06 EP EP22785374.4A patent/EP4319770A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513514A5 (enExample) | ||
| JP2024513958A5 (enExample) | ||
| Shimasaki et al. | NK cells for cancer immunotherapy | |
| KR102883631B1 (ko) | 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법 | |
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| JP2024513522A5 (enExample) | ||
| Rezvani et al. | The application of natural killer cell immunotherapy for the treatment of cancer | |
| JP7575104B2 (ja) | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 | |
| JP2024515169A5 (enExample) | ||
| Giang et al. | Nanoparticles engineered as artificial antigen-presenting cells induce human CD4+ and CD8+ Tregs that are functional in humanized mice | |
| JP7467414B2 (ja) | 改良したｔ細胞治療方法 | |
| Wei et al. | Chimeric antigen receptor T-cell therapy for T-ALL and AML | |
| Omer et al. | Enhancing natural killer cell targeting of pediatric sarcoma | |
| EP4062920A1 (en) | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product | |
| JP2024541081A (ja) | 低下したｔｇｆ－ベータ受容体シグナル伝達を有する遺伝子操作されたｔ細胞 | |
| Messaoudene et al. | Patient’s natural killer cells in the era of targeted therapies: role for tumor killers | |
| Fang et al. | Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy | |
| JP2022023136A5 (enExample) | ||
| Peng et al. | A cultured malignant B-1 line serves as a model for Richter's syndrome. | |
| Zhang et al. | Paving the way towards universal chimeric antigen receptor therapy in cancer treatment: current landscape and progress | |
| CN114929865A (zh) | 作为过继细胞疗法的基因工程化双阴性t细胞 | |
| CN119095953A (zh) | 细胞表面受体的表位工程 | |
| Beelen et al. | Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy | |
| EP3228701A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
| Sánchez et al. | Beyond CAR-T cells: Natural killer cells immunotherapy |